arrow
P

Philip Sutera

university of rochester
H指数:15
被引数:1,013

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008

Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski等人. 去势敏感转移性前列腺癌中无前列腺特异性抗原进展的放射学进展:ENZAMET试验(ANZUP 1304)的回顾性分析. 欧洲泌尿肿瘤学. 即将发表. http://dx.doi.org/10.1016/j.euo.2026.01.008

2026-04-110
PRE
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy

转移灶定向治疗的基因组预测因子:含或不含雄激素剥夺治疗

2025-09-200
PREAI
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
2025-01-010
PRE
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

寡转移去势敏感性前列腺癌转移导向治疗联合或不联合雄激素阻断治疗的多机构分析

2024-12-010
OA
Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics

机器学习使用前列腺特异性膜抗原 (PSMA) PET放射组学预测寡转移去势敏感性前列腺癌 (omCSPC) 的常规成像无转移生存期 (MFS)

2024-10-011
PRE
Prognostic Significance of Immune Cell Infiltration in Muscle- invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712
2024-10-010
OA
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer

在同步低容量转移性去势敏感性前列腺癌中,用于前列腺定向治疗的预测性基因组生物标志物的鉴定

2024-04-012
OA
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer
2023-12-0112
OA
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
2023-07-019
OA
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer
2023-04-019
OAAI
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics
2022-01-1119
OA